The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 27, No. 9, pp. 1073-1081.
© 1993 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graves, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graves, N.


Research Articles

Felbamate

NM Graves

OBJECTIVE: To provide an up-to-date review of the current literature on felbamate (FBM) and its use as an antiepileptic medication (AEM). DATA SOURCES: All published literature (manuscripts and abstracts) on FBM was reviewed. The initial bibliography (up to September 1992) was provided by the manufacturer (Carter-Wallace Laboratories); subsequent literature was obtained from American Epilepsy Society presentations in December 1992 and manuscripts published up to January 1993. STUDY SELECTION/DATA EXTRACTION: All pertinent literature was reviewed. Information from the publications was abstracted and organized by the author. DATA SYNTHESIS: FBM is effective in complex partial seizures either as monotherapy or as an adjunct in patients receiving other AEMs. In addition, it has shown efficacy in some seizures associated with the Lennox-Gastaut syndrome. Adverse effects appear to be mild. When FBM is given as monotherapy, the primary adverse effects are insomnia and weight loss. Patients receiving multiple AEMs may have increased adverse effects. CONCLUSIONS: FBM appears to be an effective new AEM. Additional studies as to its role in newly diagnosed and pregnant patients are needed. Pharmacokinetic studies in children, patients with renal failure, and patients on nonepilepsy drugs also are needed.


This article has been cited by other articles:


Home page
Mayo Clin Proc.Home page
R. G. Jarrar and J. R. Buchhalter
Therapeutics in Pediatric Epilepsy, Part 1: The New Antiepileptic Drugs and the Ketogenic Diet
Mayo Clin. Proc., March 1, 2003; 78(3): 359 - 370.
[Abstract] [PDF]


Home page
Journal of Pharmacy PracticeHome page
J. L. Scala and C. Y. Poon
Anticonvulsant Therapy in Children: An Update
Journal of Pharmacy Practice, February 1, 1996; 9(1): 27 - 41.
[Abstract] [PDF]


Home page
J Child NeurolHome page
W. E. Dodson and B. F.D. Bourgeois
Pharmacology and Therapeutic Aspects of Antiepileptic Drugs in Pediatrics
J Child Neurol, October 1, 1994; 9(2_suppl): 281 - 287.
[Abstract] [PDF]


Home page
Arch Fam MedHome page
J. C. Cloyd, T. E. Lackner, and I. E. Leppik
Antiepileptics in the Elderly: Pharmacoepidemiology and Pharmacokinetics
Arch Fam Med, July 1, 1994; 3(7): 589 - 598.
[Abstract] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1993 by Harvey Whitney Books Company.